Complete Resection at TURBT in Muscle-Invasive Bladder Cancer

Primary Advantages of Complete Resection

A visually and microscopically complete TURBT is associated with improved patient outcomes in muscle-invasive bladder cancer, serving as both optimal staging and potentially therapeutic intervention, according to the National Comprehensive Cancer Network 1.
Complete resection enables more accurate pathologic staging, which is essential for treatment selection and risk stratification, as recommended by the National Comprehensive Cancer Network 1, 2.
Adequate resection with muscle in the specimen is mandatory for accurate staging, as the presence of muscularis propria is essential for distinguishing non-muscle-invasive from muscle-invasive disease, according to the National Comprehensive Cancer Network and Annals of Oncology 1, 2, 3.

For MIBC, resection should extend deep into underlying detrusor muscle, with specimens sent separately to ensure adequate pathologic evaluation, as suggested by Annals of Oncology and The Journal of Urology 4, 6.
Bimanual examination under anesthesia should document tumor characteristics and assess for extravesical extension, according to the National Comprehensive Cancer Network and Annals of Oncology 7, 3.

Maximal TURBT is the primary treatment option for cT2, cT3, and cT4a disease when pursuing bladder preservation with concurrent chemoradiotherapy, as recommended by the National Comprehensive Cancer Network 1, 2.
Complete TURBT before chemoradiotherapy significantly improves survival outcomes in trimodality protocols, according to the National Comprehensive Cancer Network 1.

Retrospective data shows that incomplete initial resection is common, with 70% of patients having incomplete resection, and 30% having macroscopic residual tumor, as reported in The Journal of Urology 9.
Cauterization should be minimized to prevent tissue destruction that compromises pathologic evaluation, as suggested by The Journal of Urology 9.
Imaging should be performed before TURBT when invasive tumor is suspected to allow better anatomic characterization without interference from post-TURBT inflammation, according to Annals of Oncology 4, 5.